Welcome to our dedicated page for Outdoor Holding Company SEC filings (Ticker: POWWP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating ammunition capacity metrics or GunBroker.com fee disclosures inside AMMO Inc’s dense SEC paperwork can feel like sorting brass at the range. From multi-segment accounting notes to firearms-specific regulations, every 10-K and 8-K packs details that move the stock. That’s why investors searching for “AMMO Inc SEC filings explained simply” or “AMMO Inc 8-K material events explained” land here first.
Stock Titan’s AI decodes each document the moment it hits EDGAR. Want the latest AMMO Inc quarterly earnings report 10-Q filing? We flag ammunition gross margins, marketplace GMV, and cash burn instantly. Need “AMMO Inc insider trading Form 4 transactions” or “AMMO Inc executive stock transactions Form 4” in real-time? Our alerts surface every purchase or sale within seconds. Even complex schedules in the proxy statement become clear with our AI-powered summaries, turning “AMMO Inc proxy statement executive compensation” into concise tables you can scan in minutes.
Every form—10-K, 10-Q, 8-K, S-3, DEF 14A, Form 4—lives in one place, updated live and paired with expert analysis. Use our guidance for “AMMO Inc earnings report filing analysis,” compare segment results quarter-over-quarter, or track gun-law litigation disclosures without paging through footnotes. Whether you’re “understanding AMMO Inc SEC documents with AI” or verifying “AMMO Inc annual report 10-K simplified,” our platform gives you the firearm-industry context traditional feeds miss. Save hours, catch key numbers, and never miss an “AMMO Inc Form 4 insider transactions real-time” alert again.
Hudson Global, Inc. (HSON) has filed a Form S-4 to register securities connected with its planned all-stock merger with Star Equity Holdings, Inc. (STRR). Under the Agreement and Plan of Merger dated 21 May 2025, Star will merge into HSON Merger Sub, becoming a wholly-owned subsidiary of Hudson. Each share of Star common stock will be exchanged for 0.23 shares of Hudson common stock, while each share of Star’s 10.0% Series A preferred stock will convert 1-for-1 into newly created Hudson Series A preferred stock. No cash will be paid for fractional shares.
Post-transaction ownership is expected to be approximately 79 % Hudson shareholders / 21 % former Star shareholders on a fully-diluted basis. The transaction requires: (i) approval of Hudson shareholders for the issuance of >5 % new shares (Nasdaq Rule 5635(a)), plus routine annual-meeting matters; and (ii) approval of Star shareholders to adopt the merger agreement. Meetings are scheduled in Old Greenwich, CT, with a record date of 14 July 2025.
Hudson will also seek to amend its 2009 Incentive Stock and Awards Plan to add 400,000 common shares and permit issuance of up to 175,000 preferred shares. Three Star-designated directors will join an expanded seven-member Hudson board at closing; existing Hudson officers will remain in place.
The agreement contains reciprocal $250,000 termination fees plus up to $250,000 expense reimbursement should either party abandon the deal and subsequently enter a competing transaction within nine months. Neither company’s shareholders are entitled to appraisal rights.
Key risks highlighted for investors include market fluctuation in Hudson’s share price (which directly affects the value received by Star holders), potential dilution for Hudson investors, and conflicts of interest—Hudson CEO Jeffrey E. Eberwein also serves on Star’s board. Both boards unanimously recommend voting “FOR” their respective proposals.
Soluna Holdings, Inc. (Nasdaq: SLNH / SLNHP) filed a Form 8-K under Item 8.01 (Other Events). The Board of Directors set August 18, 2025 as the date of the Company’s 2025 Annual Meeting of Stockholders and designated June 30, 2025 as the record date for determining shareholders entitled to notice of, and to vote at, the meeting. Because the new meeting date is more than 30 days later than last year’s meeting, the Company has reset the Rule 14a-8 deadline for shareholder proposals: submissions must be received by the Corporate Secretary no later than July 15, 2025 to be eligible for inclusion in the proxy statement. Proposals must also satisfy Nevada law, SEC regulations, and the Company’s Bylaws. The specific time and location of the meeting will be disclosed in the forthcoming proxy statement.
No financial results, transactions, or strategic changes were disclosed; the filing is limited to scheduling and procedural matters.
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
The Form 4 filed on 07/02/2025 reports that Ecolab Inc. (ECL) director Michael Larson acquired 126.18 shares of common stock on 06/30/2025. The transaction was coded “A” (acquisition) and carried a stated price of $0.00 because the shares were credited under the dividend-reinvestment feature of the company’s 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. After the reinvestment, Larson’s direct holding rose to 17,248.37 shares. No sales, options, or other derivative activities were disclosed. Given the modest size of the purchase—representing well under 1 % of outstanding shares and a dollar value likely below $30 k—the filing appears routine and is unlikely to have a material impact on Ecolab’s share price or governance structure.
FAQ
What is the current stock price of Outdoor Holding Company (POWWP)?
What are the core business segments of AMMO Inc?
How does AMMO Inc generate revenue?
What distinguishes AMMO Inc’s manufacturing process?
How does GunBroker.com enhance the company’s business model?
Who are the primary customers of AMMO Inc?
What operational challenges does AMMO Inc face?
How does AMMO Inc differentiate itself from competitors?
What measures are in place to ensure product quality at AMMO Inc?
